Charlotte Schubert is a science writer and reporter with a focus on the life sciences in the Pacific Northwest. She is a contributing editor at GeekWire and also writes for the University of Miami. With a Ph.D. and expertise in CRISPR technology, Charlotte brings a unique perspective to her reporting on biotech startups, medical research, and scientific advancements in the Seattle area.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Seattle, United States (Local)
Charlotte Schubert's coverage predominantly focuses on the local tech and biotech sectors, particularly in Seattle. She heavily features press releases and private sector announcements related to biotechnology, medical research, startups, and AI developments within the region. Pitches for her should highlight new scientific breakthroughs, innovations in technology or business strategies from local companies or institutions.
Given her focus on specific businesses and their announcements, she may be interested in pitches that offer exclusive insights into these companies' future plans or recent developments. Additionally, experts with a strong understanding of the Seattle business landscape would likely appeal to Charlotte.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Charlotte Schubert
A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.
Share Access to new, targeted drugs is often limited by the ability of national health care systems and insurance companies to pay.
By: Charlotte Schubert
The director of the Sylvester Myeloma Research Institute is using a family approach to build a nationally respected multiple myeloma program
By: Charlotte Schubert
CDCguidelines for anal cancer screening in people with HIV are based in part by data compiled by Sylvester Comprehensive Cancer Center.
By: Charlotte Schubert
Sylvester physician-scientists are devoting their energies to stopping liver cancer before it develops and addressing access disparities.
By: Charlotte Schubert
The ilingual Sylvester thoracic oncologist and researcher is devoted to understanding and advancing health equity in cancer patients.
By: Charlotte Schubert
Sylvester researchers explore new options for acute myeloid leukemia patients in a new commentary for JAMA Oncology.
By: Charlotte Schubert
In a laboratory near downtown Seattle on the shores of Lake Union, Hetu Kamisetty is helping build what he says is the biotech company of the future.
By: Charlotte Schubert
A clinical study evaluated whether two biomarkers could predict disease recurrence in head and neck cancer patients. The presence of elevated levels of either biomarker in saliva was associated with recurrence risk. Further development of the approach could lead to new ways to predict if cancer will come back.
By: Charlotte Schubert
The NCI recently renewed Sylvester’s designation as the only NCI-designated cancer center in South Florida.
(833) 317-6278 
